Ask AI
ProCE Banner Activity

BICSTaR: Real-world Switch to BIC/FTC/TAF in Treatment-Experienced People Living With HIV and Detectable HIV-1 RNA

Conference Coverage
Slideset

In this real-world, observational, prospective study, treatment-experienced people living with HIV and detectable HIV-1 RNA who switched from a failing regimen to BIC/FTC/TAF had high rates of virologic suppression over 24 months. 

Released: July 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the International AIDS Society.

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions